



## BioLineRx to Report Second Quarter 2012 Results on August 15, 2012

August 2, 2012

Jerusalem, Israel, August 2, 2012 --- BioLineRx Ltd. (NASDAQ: [BLRX](#)) (TASE: [BLRX](#)), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended June 30, 2012 on Wednesday, August 15, 2012, before the U.S. markets open.

The Company will host a conference call on Wednesday, August 15 at 10:00 a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, [www.bioglinerx.com](http://www.bioglinerx.com), and [www.kcsa.com](http://www.kcsa.com). Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-0609 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at [www.bioglinerx.com](http://www.bioglinerx.com) or [www.kcsa.com](http://www.kcsa.com). A dial-in replay of the call will be available until August 18, 2012; please dial 1-888-782-4291 from the U.S. or +972-3-9255901 internationally.

### About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia is currently undergoing a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Icaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) has commenced a Phase II trial. In addition, BioLineRx has eleven products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization.

For more information on BioLineRx, please visit [www.bioglinerx.com](http://www.bioglinerx.com).

### Contacts:

Garth Russell / Todd Fromer

KCSA Strategic Communications

1-212-896-1250 / 1-212-896-1215

[grussell@kcsa.com](mailto:grussell@kcsa.com) / [tfromer@kcsa.com](mailto:tfromer@kcsa.com)

Tsipi Haitovsky

Public Relations

+972-3-6240871

[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)